LT2970202T - Piridinilo ir kondensuoto piridinilo triazolono dariniai - Google Patents

Piridinilo ir kondensuoto piridinilo triazolono dariniai

Info

Publication number
LT2970202T
LT2970202T LTEP14719130.8T LT14719130T LT2970202T LT 2970202 T LT2970202 T LT 2970202T LT 14719130 T LT14719130 T LT 14719130T LT 2970202 T LT2970202 T LT 2970202T
Authority
LT
Lithuania
Prior art keywords
pyridinyl
fused
triazolone derivatives
derivatives
triazolone
Prior art date
Application number
LTEP14719130.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
John David Lawson
Mark Sabat
Nicholas Scorah
Christopher Smith
Phong H. Vu
Haixia Wang
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of LT2970202T publication Critical patent/LT2970202T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP14719130.8T 2013-03-11 2014-03-10 Piridinilo ir kondensuoto piridinilo triazolono dariniai LT2970202T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776445P 2013-03-11 2013-03-11
PCT/US2014/022801 WO2014164558A1 (en) 2013-03-11 2014-03-10 Pyridinyl and fused pyridinyl triazolone derivatives

Publications (1)

Publication Number Publication Date
LT2970202T true LT2970202T (lt) 2017-06-12

Family

ID=50543655

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14719130.8T LT2970202T (lt) 2013-03-11 2014-03-10 Piridinilo ir kondensuoto piridinilo triazolono dariniai

Country Status (43)

Country Link
US (4) US9402841B2 (enExample)
EP (2) EP3235814B1 (enExample)
JP (2) JP6271700B2 (enExample)
KR (1) KR102300612B1 (enExample)
CN (1) CN105121427B (enExample)
AP (1) AP2015008646A0 (enExample)
AR (1) AR095198A1 (enExample)
AU (1) AU2014249248B2 (enExample)
BR (1) BR112015020264B1 (enExample)
CA (1) CA2899948C (enExample)
CL (1) CL2015002370A1 (enExample)
CR (1) CR20150470A (enExample)
CY (1) CY1119356T1 (enExample)
DK (1) DK2970202T3 (enExample)
DO (1) DOP2015000184A (enExample)
EA (1) EA028584B1 (enExample)
EC (1) ECSP15042779A (enExample)
ES (2) ES2624439T3 (enExample)
GE (1) GEP201706778B (enExample)
HK (1) HK1245256B (enExample)
HR (1) HRP20170622T1 (enExample)
HU (1) HUE032720T2 (enExample)
IL (1) IL240353B (enExample)
JO (1) JO3377B1 (enExample)
LT (1) LT2970202T (enExample)
MA (1) MA38391B1 (enExample)
ME (1) ME02693B (enExample)
MX (1) MX364527B (enExample)
MY (1) MY183927A (enExample)
PE (1) PE20151889A1 (enExample)
PH (1) PH12015502046B1 (enExample)
PL (1) PL2970202T3 (enExample)
PT (1) PT2970202T (enExample)
RS (1) RS55879B1 (enExample)
SG (1) SG11201506112QA (enExample)
SI (1) SI2970202T1 (enExample)
SM (1) SMT201700218T1 (enExample)
TN (1) TN2015000342A1 (enExample)
TW (1) TWI637950B (enExample)
UA (1) UA114944C2 (enExample)
UY (1) UY35376A (enExample)
WO (1) WO2014164558A1 (enExample)
ZA (1) ZA201505996B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
KR20220027271A (ko) 2014-02-21 2022-03-07 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
CN104447530A (zh) * 2014-12-11 2015-03-25 苏州欧凯医药技术有限公司 4-甲基-2,6-二羧基吡啶的制备方法
CA2970723C (en) 2014-12-18 2023-09-05 Principia Biopharma Inc. Treatment of pemphigus
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
UY37046A (es) 2015-12-24 2017-07-31 Takeda Pharmaceuticals Co Cocristal, método de produccion del mismo,y medicamento que contiene dicho cocristal
WO2017122175A1 (en) * 2016-01-13 2017-07-20 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
DK3436447T3 (da) * 2016-03-31 2021-09-13 Takeda Pharmaceuticals Co Isoquinolinyl-triazolon-komplekser
WO2018005849A1 (en) 2016-06-29 2018-01-04 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
KR102459858B1 (ko) * 2019-04-02 2022-10-27 연세대학교 산학협력단 신규 화합물 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 조성물
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TWI877239B (zh) 2019-10-14 2025-03-21 美商普林斯匹亞生物製藥公司 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022014149A2 (pt) 2020-01-22 2022-09-27 Principia Biopharma Inc Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)-1h-pirazolo[3,4-d]pirimidina-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrila
AU2021325431B2 (en) 2020-08-14 2024-01-18 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2025116652A1 (ko) * 2023-11-30 2025-06-05 주식회사 지엔티파마 자가면역 질환 치료용 조성물 및 방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5733849A (en) * 1996-03-15 1998-03-31 Rohm And Haas Company Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE269295T1 (de) 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
ATE346064T1 (de) * 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
CN101421269A (zh) 2006-01-13 2009-04-29 环状药物公司 酪氨酸激酶抑制剂及其用途
US8053456B2 (en) * 2006-05-25 2011-11-08 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
JP2009541252A (ja) 2006-06-20 2009-11-26 エフ.ホフマン−ラ ロシュ アーゲー テトラリン及びインダン誘導体ならびにそれらの使用
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
EA017865B1 (ru) 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
ES2462642T3 (es) 2007-12-14 2014-05-26 F. Hoffmann-La Roche Ag Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
CA2710462C (en) 2008-02-05 2015-11-24 F. Hoffmann-La Roche Ag Pyridinones and pyridazinones
CN103709148B (zh) 2008-06-24 2015-10-21 霍夫曼-拉罗奇有限公司 取代的吡啶-2-酮和哒嗪-3-酮
JP5490789B2 (ja) 2008-07-02 2014-05-14 エフ.ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての新規なフェニルピラジノン
ES2552681T3 (es) 2008-07-15 2015-12-01 F. Hoffmann-La Roche Ag Nuevas fenil-imidazopiridinas y piridazinas
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
US8497265B2 (en) 2010-05-13 2013-07-30 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
MX367623B (es) 2010-10-20 2019-08-29 Gruenenthal Gmbh 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
JP2013544321A (ja) 2010-11-10 2013-12-12 エスティーシー. ユーエヌエム ゼロ原子価金属粒子用エアロゾル還元/膨張合成(a−res)
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
ECSP15042779A (es) 2017-08-31
TWI637950B (zh) 2018-10-11
PH12015502046A1 (en) 2016-01-18
UY35376A (es) 2014-10-31
US20140256734A1 (en) 2014-09-11
ME02693B (me) 2017-10-20
MA38391A1 (fr) 2018-01-31
SI2970202T1 (sl) 2017-07-31
IL240353A0 (en) 2015-09-24
US10307414B2 (en) 2019-06-04
EP2970202A1 (en) 2016-01-20
BR112015020264A2 (pt) 2017-07-18
MA38391B1 (fr) 2018-09-28
PL2970202T3 (pl) 2017-08-31
DK2970202T3 (en) 2017-05-08
GEP201706778B (en) 2017-11-27
JP2018076357A (ja) 2018-05-17
EA201591686A1 (ru) 2015-12-30
WO2014164558A1 (en) 2014-10-09
PE20151889A1 (es) 2015-12-26
CN105121427B (zh) 2018-04-10
CA2899948C (en) 2021-11-16
AU2014249248A1 (en) 2015-08-20
MX2015011533A (es) 2016-02-03
HK1245256B (en) 2019-09-27
CN105121427A (zh) 2015-12-02
PT2970202T (pt) 2017-05-03
AR095198A1 (es) 2015-09-30
CR20150470A (es) 2016-01-11
TN2015000342A1 (en) 2017-01-03
UA114944C2 (uk) 2017-08-28
HUE032720T2 (en) 2017-10-30
MX364527B (es) 2019-04-30
CA2899948A1 (en) 2014-10-09
JO3377B1 (ar) 2019-03-13
EP3235814A1 (en) 2017-10-25
HK1220183A1 (en) 2017-04-28
EP3235814B1 (en) 2018-12-12
EP2970202B1 (en) 2017-02-01
RS55879B1 (sr) 2017-08-31
AU2014249248B2 (en) 2017-08-17
KR20150126687A (ko) 2015-11-12
US9402841B2 (en) 2016-08-02
JP2016512515A (ja) 2016-04-28
AP2015008646A0 (en) 2015-08-31
US20160310483A1 (en) 2016-10-27
MY183927A (en) 2021-03-17
NZ710852A (en) 2020-12-18
ES2714166T3 (es) 2019-05-27
US20180015083A1 (en) 2018-01-18
HRP20170622T1 (hr) 2017-06-30
PH12015502046B1 (en) 2019-01-23
IL240353B (en) 2018-11-29
US20190224190A1 (en) 2019-07-25
CY1119356T1 (el) 2018-02-14
TW201522328A (zh) 2015-06-16
KR102300612B1 (ko) 2021-09-09
US9801872B2 (en) 2017-10-31
SG11201506112QA (en) 2015-09-29
ES2624439T3 (es) 2017-07-14
JP6271700B2 (ja) 2018-01-31
EA028584B1 (ru) 2017-12-29
JP6462842B2 (ja) 2019-01-30
DOP2015000184A (es) 2015-11-30
CL2015002370A1 (es) 2016-03-11
SMT201700218T1 (it) 2017-07-18
ZA201505996B (en) 2016-11-30
BR112015020264B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
ZA201505996B (en) Pyridinyl and fused pyridinyl triazolone derivatives
ZA201602501B (en) Pyrrolobenzodiazepines and conjugates thereof
IL241532B (en) Pyrrolobenzodiazepines and their conjugates
ZA201506668B (en) Pyrrolobenzodiazepines and conjugates thereof
ZA201505753B (en) Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) Pyrrolobenzodiazepines and conjugates thereof
IL240788A0 (en) Heterocyclic compounds and their uses
PT2845498T (pt) Bolsa para tabaco
GB201316592D0 (en) Fusion protein
ZA201507657B (en) Pyridin-4-yl derivatives
IL244383A0 (en) Triazolone compounds and their uses
PL2978326T3 (pl) Papierosy i ich budowa
IL245597A0 (en) Anti-neuroinflammatory and protective compounds in Achillea fragrantissima - implications for inflammatory and neurodegenerative diseases
GB201304115D0 (en) Fusion ploypeptide
GB201301120D0 (en) Improvements in joint forming devices
GB201304697D0 (en) Shopping aid